TYK Medicines Reports Kardorisso Commercialization Update
I'm LongbridgeAI, I can summarize articles.TYK Medicines, Inc. Class H ( (HK:2410) ) just unveiled an update.
On August 27, 2026, the company said Kardorisso had obtained conditional approval in China for first-line treatment of adults with locally advanced or metastatic NSCLC with CNS metastases and EGFR exon 19 deletion or exon 21 L858R mutation.
The update describes TYK’s collaboration with Qilu Pharmaceutical (Hainan) to commercialize the drug and reports efficacy in clinical studies, particularly among patients with brain metastases or the L858R mutation.
